

**REMARKS**

**PENDING CLAIMS**

Claim 10, 12-20 and 22-35 have been canceled. Allowed claims 1, 3-9 and 48-55 remain in the patent application.

***Rejections under 35 U.S.C. 112***

**Claim 10, 12-20 and 22-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which application regards as the invention.**

This rejection is rendered moot in view of the cancellation of the rejected claims, and should be withdrawn.

***Rejections under 35 U.S.C. 103 (a)***

**Claim 10,12-20, 22, 24, 32 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 131 277 in view of Yang et al. 6,042,754.**

This rejection is rendered moot in view of the cancellation of the rejected claims, and should be withdrawn.

**Claims 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 131 277 in view of Yang et al. 6,042,754 as applied to claim 22, and further in view of either Yang et al. 6,015,512 or Lefebvre 5,458,820.**

This rejection is rendered moot in view of the cancellation of the rejected claims, and should be withdrawn.

**Claims 25-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 131 277 in view of Yang et al. 6,042,754 as applied to claim 10, and further in view of WO 00/53401 (WO '401) Abstract.**

This rejection is rendered moot in view of the cancellation of the rejected claims, and should be withdrawn.

**Allowable Subject Matter**


Claims 1, 3-9 and 48-55 are allowed.

**CONCLUSION**

Applicants believe that the claims, as presented, are in conditions for allowance.

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 50-2965.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Sheng-Hsin Hu', is written over a horizontal line.

Sheng-Hsin Hu

Reg. No. 50,328

(678) 415-3171

Date: 5/16/2007

Novartis

Corporate Intellectual Property

One Health Plaza, Building 104

East Hanover, NJ 07936-1080